132 related articles for article (PubMed ID: 11012228)
1. In vivo biological effects of various forms of thrombopoietin in a murine model of transient pancytopenia.
Thomas GR; Thibodeaux H; Errett CJ; Mathias J; Marian M; Meng G; Vandlen RL; Eaton DL
Stem Cells; 1996; 14 Suppl 1():246-55. PubMed ID: 11012228
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin: biology and clinical potentials.
Miyazaki H; Kato T
Int J Hematol; 1999 Dec; 70(4):216-25. PubMed ID: 10643146
[TBL] [Abstract][Full Text] [Related]
3. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation.
Wagemaker G; Neelis KJ; Hartong SC; Wognum AW; Thomas GR; Fielder PJ; Eaton DL
Stem Cells; 1998; 16(6):375-86. PubMed ID: 9831863
[TBL] [Abstract][Full Text] [Related]
5. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
Molineux G; Hartley C; McElroy P; McCrea C; Kerzic P; McNiece I
Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
[TBL] [Abstract][Full Text] [Related]
6. Thrombopoietin accelerates platelet, red blood cell, and neutrophil recovery in myelosuppressed mice.
Grossmann A; Lenox J; Ren HP; Humes JM; Forstrom JW; Kaushansky K; Sprugel KH
Exp Hematol; 1996 Aug; 24(10):1238-46. PubMed ID: 8765500
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human thrombopoietin: clinical experience and in vivo biology.
Vadhan-Raj S
Semin Hematol; 1998 Jul; 35(3):261-8. PubMed ID: 9685172
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic modeling of pegylated thrombopoietin mimetic peptide (PEG-TPOm) after single intravenous dose administration in healthy subjects.
Samtani MN; Perez-Ruixo JJ; Brown KH; Cerneus D; Molloy CJ
J Clin Pharmacol; 2009 Mar; 49(3):336-50. PubMed ID: 19246731
[TBL] [Abstract][Full Text] [Related]
9. Native thrombopoietin: structure and function.
Kato T; Matsumoto A; Ogami K; Tahara T; Morita H; Miyazaki H
Stem Cells; 1998; 16(5):322-8. PubMed ID: 9766811
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.
Wolff SN; Herzig R; Lynch J; Ericson SG; Greer JP; Stein R; Goodman S; Benyunes MC; Ashby M; Jones DV; Fay J
Bone Marrow Transplant; 2001 Feb; 27(3):261-8. PubMed ID: 11277173
[TBL] [Abstract][Full Text] [Related]
11. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
12. Further examination of various administration protocols of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia in myelosuppressed mice.
Akahori H; Ozai M; Ida M; Shibuya K; Kato T; Miyazaki H
Ther Apher; 1998 Feb; 2(1):58-64. PubMed ID: 10227790
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of hematopoietic progenitor cells towards the myeloid and B-lymphoid lineage by hepatocyte growth factor (HGF) and thrombopoietin (TPO) together with early acting cytokines.
Grassinger J; Mueller G; Zaiss M; Kunz-Schughart LA; Andreesen R; Hennemann B
Eur J Haematol; 2006 Aug; 77(2):134-44. PubMed ID: 16856909
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of recombinant TPO in murine And nonhuman primate models for myelosuppression and stem cell transplantation.
Wagemaker G; Neelis KJ; Hartong SCC ; Wognum AW; Thomas GR; Fielder PJ; Eaton DL
Stem Cells; 1998; 16 Suppl 2():127-41. PubMed ID: 11012185
[TBL] [Abstract][Full Text] [Related]
15. Disparate effects of interleukin 11 and thrombopoietin on megakaryocytopoiesis in vitro.
Taguchi K; Saitoh M; Arai Y; Momose K; Ogawa Y; Yasuda S; Miyata K
Cytokine; 2001 Sep; 15(5):241-9. PubMed ID: 11594788
[TBL] [Abstract][Full Text] [Related]
16. Effects of Mpl ligands on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Kelly AB
Stem Cells; 1998; 16 Suppl 2():107-19. PubMed ID: 11012183
[TBL] [Abstract][Full Text] [Related]
17. A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells.
Neelis KJ; Visser TP; Dimjati W; Thomas GR; Fielder PJ; Bloedow D; Eaton DL; Wagemaker G
Blood; 1998 Sep; 92(5):1586-97. PubMed ID: 9716586
[TBL] [Abstract][Full Text] [Related]
18. Clinical findings with the first generation of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2010 Jul; 47(3):249-57. PubMed ID: 20620436
[TBL] [Abstract][Full Text] [Related]
19. Determination of thrombopoietin-derived peptides recognized by both cellular and humoral immunities in healthy donors and patients with thrombocytopenia.
Takedatsu H; Yoshimoto K; Okamura T; Miyazaki H; Kuwaki T; Sata M; Itoh K
Stem Cells; 2005 Aug; 23(7):975-82. PubMed ID: 16043461
[TBL] [Abstract][Full Text] [Related]
20. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
Newland A
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
